Abstract
Currently, 70% to 80% of patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, followed by surgical resection of the residual tumor. The prognosis, however, is uniformly poor for patients who fail to respond to induction chemotherapy. In this report, we describe a patient with retroperitoneal choriocarcinoma and multiple lung metastases, who was refractory to cisplatin-based chemotherapy, but who achieved a durable marker-negative partial response after 2 cycles of high-dose chemotherapy, supported by autologous, peripheral blood stem cell transplantation. The patient is now alive and well, without recurrence, more than 24 months after this therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 261-264 |
| Number of pages | 4 |
| Journal | International Journal of Clinical Oncology |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Advanced choriocarcinoma
- High-dose chemotherapy
- Peripheral blood stem cell transplantation
ASJC Scopus subject areas
- Oncology
Cite this
Treatment of refractory metastatic choriocarcinoma with tandem high- dose chemotherapy supported by peripheral blood stem cell transplantation : A case report. / Kawanishi, Rika; Bessho, Akihiro; Ueoka, Hiroshi; Tabata, Masahiro; Shinagawa, Katsuji; Chikamori, Kenichi; Kawai, Haruyuki; Horita, Naokatsu; Harada, Mine.
In: International Journal of Clinical Oncology, Vol. 3, No. 4, 1998, p. 261-264.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of refractory metastatic choriocarcinoma with tandem high- dose chemotherapy supported by peripheral blood stem cell transplantation
T2 - A case report
AU - Kawanishi, Rika
AU - Bessho, Akihiro
AU - Ueoka, Hiroshi
AU - Tabata, Masahiro
AU - Shinagawa, Katsuji
AU - Chikamori, Kenichi
AU - Kawai, Haruyuki
AU - Horita, Naokatsu
AU - Harada, Mine
PY - 1998
Y1 - 1998
N2 - Currently, 70% to 80% of patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, followed by surgical resection of the residual tumor. The prognosis, however, is uniformly poor for patients who fail to respond to induction chemotherapy. In this report, we describe a patient with retroperitoneal choriocarcinoma and multiple lung metastases, who was refractory to cisplatin-based chemotherapy, but who achieved a durable marker-negative partial response after 2 cycles of high-dose chemotherapy, supported by autologous, peripheral blood stem cell transplantation. The patient is now alive and well, without recurrence, more than 24 months after this therapy.
AB - Currently, 70% to 80% of patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, followed by surgical resection of the residual tumor. The prognosis, however, is uniformly poor for patients who fail to respond to induction chemotherapy. In this report, we describe a patient with retroperitoneal choriocarcinoma and multiple lung metastases, who was refractory to cisplatin-based chemotherapy, but who achieved a durable marker-negative partial response after 2 cycles of high-dose chemotherapy, supported by autologous, peripheral blood stem cell transplantation. The patient is now alive and well, without recurrence, more than 24 months after this therapy.
KW - Advanced choriocarcinoma
KW - High-dose chemotherapy
KW - Peripheral blood stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=0031706327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031706327&partnerID=8YFLogxK
U2 - 10.1007/BF02489844
DO - 10.1007/BF02489844
M3 - Article
AN - SCOPUS:0031706327
VL - 3
SP - 261
EP - 264
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 4
ER -